Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deltex1 protein lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Illinois Chicago
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Deltex1 protein lipid nanoparticles (Dtx1-LNPs) are a preclinical-stage therapeutic designed to treat T-cell acute lymphoblastic leukemia (T-ALL). The drug consists of the wildtype, full-length Deltex1 (Dtx1) protein, an E3 ubiquitin ligase, encapsulated within targeted lipid nanoparticles for delivery to human T-ALL cells. Deltex1 acts as a natural inhibitor of Notch1 signaling by interacting with the Transcriptional Activation Domain (TAD) of the Notch1 receptor and promoting its degradation. This mechanism addresses the hyperactive Notch1 signaling that drives leukemia in the majority of T-ALL patients. By utilizing a targeted LNP delivery system, Dtx1-LNPs aim to overcome the systemic toxicity and lack of tissue specificity associated with existing Notch1-targeting therapies like γ-secretase inhibitors and anti-Notch1 antibodies.
- Other names
- Deltex1 protein LNPsDeltex-1 protein LNPsDeltex 1 protein LNPsDtx1 protein lipid nanoparticlesDtx-1 protein lipid nanoparticlesDtx 1 protein lipid nanoparticles
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)DTX1 (E3 ubiquitin-protein ligase DTX1)
Beyond the preview
Go deeper on Deltex1 protein lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deltex1 protein lipid nanoparticles.